Koji Yamazaki
Overview
Explore the profile of Koji Yamazaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
132
Citations
914
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akamine T, Wakasu S, Matsubara T, Yamaguchi M, Yamazaki K, Hamatake M, et al.
Ann Surg Oncol
. 2025 Jan;
PMID: 39871081
No abstract available.
2.
Taniguchi Y, Tamiya A, Osuga M, Isa S, Nakamura K, Mizumori Y, et al.
Invest New Drugs
. 2025 Jan;
43(1):101-107.
PMID: 39789369
The impact of clinical stage on the effectiveness of osimertinib for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) remains unexamined. We investigated osimertinib therapeutic efficacy variation...
3.
Akamine T, Wakasu S, Matsubara T, Yamaguchi M, Yamazaki K, Hamatake M, et al.
Ann Surg Oncol
. 2024 Dec;
PMID: 39681715
Background: Sublobar resection is the standard procedure for cT1N0 stage I non-small cell lung cancer (NSCLC) size ≤2 cm. However, its efficacy for high-risk pathologic stage I cases with a...
4.
Shoji F, Minemura A, Kozuma Y, Nouno T, Takeoka H, Matsumoto A, et al.
Anticancer Res
. 2024 Oct;
44(11):5067-5080.
PMID: 39477328
Background/aim: Host microbiota dysbiosis has been recognized as a key factor in lung cancer. However, the specific diversity and composition of microbiota in lung cancer patients remain unknown. This single-center...
5.
Taniguchi Y, Tamiya A, Osuga M, Harada D, Isa S, Nakamura K, et al.
BMC Pulm Med
. 2024 Aug;
24(1):407.
PMID: 39182046
Background/aim: For patients treated with osimertinib as first-line therapy, there have been no studies comparing both progression-free survival (PFS) and overall survival (OS) according to performance status (PS). Furthermore, no...
6.
Akamine T, Takenaka T, Yano T, Okamoto T, Yamazaki K, Hamatake M, et al.
Eur J Surg Oncol
. 2024 Aug;
50(9):108374.
PMID: 39178719
Introduction: High recurrence rate following curative surgery for non-small cell lung cancer (NSCLC) presents a major clinical challenge. Understanding the site and timing of recurrence and their impact on post-recurrence...
7.
Yamaki S, Yamazaki K
Arch Virol
. 2024 Aug;
169(9):182.
PMID: 39153099
Morganella psychrotolerans is a histamine-producing bacterium that causes histamine poisoning. In this study, we isolated and characterized a novel phage, MopsHU1, that infects M. psychrotolerans. MopsHU1 is a podovirus with...
8.
Tamiya A, Osuga M, Harada D, Isa S, Taniguchi Y, Nakamura K, et al.
Lung Cancer
. 2024 Aug;
195:107917.
PMID: 39116552
Background: Several patients treated with osimertinib experience progressive disease. The aim was to clarify the mechanisms underlying resistance to osimertinib. Methods: ELUCIDATOR: A multi-centre, prospective, observational study involved chemotherapy-naive patients...
9.
Nakashima T, Yamazaki K, Uchi R, Uryu H
Case Rep Oncol
. 2024 Feb;
17(1):186-190.
PMID: 38312747
Introduction: Metallic stents are widely used to prevent airway obstruction for tracheal stenosis caused by malignant diseases. Although their efficacy has been recognized, there is no established evidence surrounding their...
10.
Kenmotsu H, Yamamoto N, Misumi T, Yoh K, Saito H, Sugawara S, et al.
J Clin Oncol
. 2023 Sep;
41(34):5242-5246.
PMID: 37656928
JCO The JIPANG study is an open-label phase III trial evaluating the efficacy of pemetrexed plus cisplatin (PemP) versus vinorelbine plus cisplatin (NP) as adjuvant chemotherapy in patients with stage...